基本信息 产品详情 公司简介 推荐产品
  • 首页
  • 个人中心
  • 委托采购
  • 采购清单
网站主页 CANTRIXIL Cantrixil
  • Cantrixil|T39586|TargetMol

Cantrixil|T39586|TargetMol

Cantrixil
2135511-22-5
￥3930 2mg 起订
上海 更新日期：2025-11-17

TargetMol中国（陶术生物）

VIP4年
联系人：邵小姐
手机：4008200310 拨打
邮箱：marketing@tsbiochem.com

产品详情:

中文名称：
Cantrixil
英文名称：
Cantrixil
CAS号：
2135511-22-5
品牌：
TargetMol
产地：
美国
保存条件：
Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
产品类别：
抑制剂
货号：
T39586

Product Introduction

Bioactivity

名称Cantrixil
描述Cantrixil (TRX-E-002-1) is a second-generation super-benzopyran (SBP) compound, derived from TRX-E-002. It elicits an increase in phosphorylated c-Jun levels, leading to caspase-mediated apoptosis in ovarian cancer cells. Cantrixil exhibits potent pan anti-cancer activity against various cancer phenotypes.
体外活性TRX-E-002-1 shows broad cytotoxic activity against ovarian, prostate and lung cancer cells, with IC 50 values of ≤0.1 μM (SK-OV-3, JAM, OVCAR-3 cells: IC 50 =0.023-0.065 μM; DU145, PC3; C4-2B cells: IC 50 =0.014-0.096 μM; A549 cells: IC 50 =0.058 μM). Activity in pancreatic and colorectal cancer cells and glioblastoma cells are more variable[1]. Cantrixil (0.2 μM; 2-24 hours) shows high levels of phosphorylated c-Jun (p-c-Jun) and low levels of phosphorylated-ERK (p-ERK)[2]. Cantrixil (2.45 μM; 2-24 hours) induces a significant increase in both caspase-3/7 and caspase-9 activity at 16 and 24 hours[2]. TRX-E-002-1 inhibits multiple cytochrome P450 drug-metabolizing enzymes, including CYP2C9, CYP2C8, CYP2C19, CYP2B6, CYP3A4, CYP2D6, CYP2A6 and CYP1A2. IC 50 values ranges from 1.5 to 75 μM (612-30,600 ng/mL)[1]. Western Blot Analysis[2]Cell Line: Ovarian cancer stem cells (OCSCs) Concentration: 0.2 μM Incubation Time: 2, 4, 8, 16, 24 hours Result: Showed higher levels of phosphorylated c-Jun (p-c-Jun) and lower levels of phosphorylated-ERK (p-ERK). Showed a time-dependent increase in p-c-Jun accompanied by a time-dependent increase in total c-Jun.
体内活性TRX-E-002-1 (100 mg/kg/day; IP; for 13-14 days) significantly inhibits tumour growth in disseminated ovarian cancer mouse model[1]. TRX-E-002-1 (100 mg/kg/day; IP; for 4 weeks) inhibits tumour growth and reduces terminal tumour burden by 77% in the recurrent ovarian cancer mouse model[1]. TRX-E-002-1 (100 mg/kg/day; IP; for 18 days) significantly reduces terminal pancreatic tumour burden in a mouse model of pancreatic cancer (human Panc-1 pancreatic tumour cells implanted orthotopically into female NOD-SCID mice)[1]. TRX-E-002-1 (100 mg/kg; IP) has a T 1/2 of 2.5 hours, a C max of 8355 ng/mL and an AUC 0-∞ of 40600 ng?h/mL[1]. Animal Model: Disseminated ovarian cancer mouse model[1]Dosage: 100 mg/kg (dissolved in 20% SBECD) Administration: IP; once daily; for 13-14 days Result: Significantly inhibited tumour growth and reduced excised tumour weight at termination by 50-72%. Animal Model: Male female Sprague-Dawley rats[1]Dosage: 100 mg/kg (Pharmacokinetic Analysis) Administration: IP Result: Had a T 1/2 of 2.5 hours, a C max of 8355 ng/mL and an AUC 0-∞ of 40600 ng?h/mL.
存储条件Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
关键字Cantrixil
相关产品Sodium citrate | L-Methionine | Gefitinib | Cysteamine hydrochloride | Alginic acid | Metronidazole | Dextran sulfate sodium salt (MW 5000) | Citric Acid Triammonium | Stavudine | Cystamine dihydrochloride | L-Ascorbic acid sodium salt | Sodium 4-phenylbutyrate
TRX-E-002-1|TargetMol

公司简介

TargetMol Chemicals Inc. 总部位于马萨诸塞州波士顿，致力于为全球生化领域科学家的研究提供专业的产品和服务。TargetMol?品牌的客户群分布于40多个国家和地区，已发展成为全球知名的化合物库和小分子化合物研究供应商。 TargetMol?可提供160多种满足不同需求的化合物库，以及多种类型的生化试剂产品，包括12000多种抑制剂、16000多种天然产物和各类多肽、抗体、生命科学试剂盒等，此外，我们还建设有CADD（计算机辅助药物设计）研究中心、药理实验室、药化合成平台三大技术中心，全方位满足客户的定制需求。 凭借我们优质的产品和服务、快速高效的全球供应链和专业的技术支持，我们将有效帮助您缩短研发周期，取得更成功的结果。

成立日期 (13年)
注册资本 566.265100万人民币
员工人数 100-500人
年营业额 ￥ 1亿以上
经营模式 贸易,工厂,试剂,定制,服务
主营行业 天然产物,生化试剂,分子生物学,分子砌块,生物技术服务

内容声明
official 进入官方账号
拨打电话 立即询价